Ottawa Regional Cancer Clinic, University of Ottawa
Open Trial
Description
NCIC CTG OV 16
A phase III study of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus paclitaxel plus carboplatin as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer.
A pilot, phase 2, single center, non-comparative, open-label study of Aromasin (Exemestane) in patients with recurrent or refractory stage 2-4 epithelial ovarian cancer.